Pfizer is terminating its research partnership with Sangamo Therapeutics, which produced a hemophilia A gene therapy. The termination comes before costly milestone payments are due for the product. Sangamo will regain all rights to the gene therapy, giroctocogene fitelparvovec, and is exploring new collaboration partners. Pfizer had reported positive Phase 3 results for the therapy, but has decided not to proceed with regulatory submissions. Commercialization challenges for hemophilia gene therapies have led to companies making difficult decisions. Sangamo is facing financial difficulties and is exploring all options to secure funding for its pipeline of genomic medicines, including the hemophilia A gene therapy.
Source link
Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia on Cusp of FDA Filing
